{
    "nct_id": "NCT06586606",
    "title": "A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Itraconazole on the Single Dose PK of MK-1708 in Healthy Participants",
    "status": "COMPLETED",
    "last_update_time": "2024-12-17",
    "description_brief": "The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine called itraconazole.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "MK-1708 (oral investigational agent, Merck)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The clinical-trial record and sponsor materials show MK-1708 is an investigational oral drug being developed by Merck for Alzheimer's disease; the study is a two-period pharmacokinetic (PK) / drug\u2013drug interaction study with itraconazole (NCT06586606). \ue200cite\ue202turn3search5\ue202turn1search0\ue201",
        "Act (key details extracted): MK-1708 is administered as an oral formulation (oral suspension) and given as single oral doses in the PK interaction study; the protocol tests MK-1708 alone and co\u2011administered with itraconazole. Sponsor: Merck (MSD). Trial identifiers and design descriptions reference Alzheimer\u2019s disease as the condition. \ue200cite\ue202turn0search2\ue202turn3search6\ue201",
        "Rationale for category: Oral administration as an oral suspension and the use of itraconazole (a standard strong CYP3A inhibitor used in small\u2011molecule DDI studies) strongly indicate MK-1708 is a small\u2011molecule investigational drug rather than a biologic; the trial is a PK/interaction study for an Alzheimer's therapeutic candidate, so it fits the 'disease-targeted small molecule' category. \ue200cite\ue202turn4search3\ue202turn3search2\ue201",
        "Uncertainty / missing info: Public trial records and sponsor pages identify MK-1708 and its intended indication (Alzheimer's) but do not disclose a molecular mechanism of action or specific molecular target (e.g., amyloid, tau). Therefore the classification is based on route/formulation and study design (oral DDI study) rather than an explicit public statement of target. \ue200cite\ue202turn3search5\ue201",
        "Sources (search results used): ClinicalTrials.gov / trial registry summary for NCT06586606 (study title and design). \ue200cite\ue202turn3search5\ue201; Merck trial listing for MK-1708. \ue200cite\ue202turn1search0\ue201; Trial listings (MedPath/CTv) showing oral dosing and Alzheimer\u2019s indication. \ue200cite\ue202turn3search2\ue202turn3search6\ue201; Papers/standards showing itraconazole is used as a strong CYP3A inhibitor in DDI/PK studies (supports inference that MK-1708 is a small\u2011molecule substrate of CYP-mediated metabolism). \ue200cite\ue202turn4search3\ue201"
    ],
    "agent_type": "S) Unknown Target",
    "explanation_agent": [
        "Reason: The trial is a Merck Phase 1 pharmacokinetic / drug\u2013drug interaction study of the oral investigational small molecule MK-1708 (co\u2011administered with itraconazole), indicating MK-1708 is a disease\u2011targeted small\u2011molecule candidate for Alzheimer\u2019s disease; however, public registries and sponsor pages do not describe a molecular mechanism or specific biological target (e.g., amyloid, tau, inflammation). \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Key extracted details \u2014 MK-1708 is administered orally as an investigational small molecule in Phase 1 PK/safety studies and is tested alone and with itraconazole (a strong CYP3A inhibitor) to assess drug\u2013drug interaction; the trial records name Alzheimer\u2019s disease as the indication but do not state a target or pathway. (Sources: ClinicalTrials.gov / Merck trial listing / trial aggregators.) \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search2\ue201",
        "Reflect: Because no authoritative public source (sponsor pages, trial registry entries, or pipeline databases) specifies MK-1708\u2019s molecular target or mechanism of action, the most appropriate CADRO category is S) Unknown Target. If additional mechanistic information (e.g., Merck investigator brochure, patent, or peer\u2011reviewed description) becomes available, the classification should be revisited and reassigned to the specific CADRO category that matches the reported mechanism. For completeness, pipeline databases also list MK-1708 with an unknown/unspecified target. \ue200cite\ue202turn1search4\ue202turn0search5\ue201"
    ]
}